HS-10382 clinical trials
HS-10382 is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain, Italy, South Korea, Australia and China registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1). The most-studied condition is Chronic Myeloid Leukemia.
Patient leaflets for HS-10382
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of HS-10382
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
|
Phase 1/2 | Recruiting | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | UK, USA, Germany, France, Spain, Italy, South Korea, Australia |
|
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT07885293 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia
|
Phase 3 | Not yet open | Jiangsu Hansoh Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with HS-10382
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about HS-10382 trials
How many clinical trials are testing HS-10382?
2 current trials in our UK, USA, Germany, France, Spain, Italy, South Korea, Australia and China registers name HS-10382 (also registered as MK-4208) as a drug or biological intervention, as of the registry sync on 22 October 2026. Completed and withdrawn studies are not counted.
Are HS-10382 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in South Korea and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors HS-10382 clinical trials?
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) and Jiangsu Hansoh Pharmaceutical Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HS-10382 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HS-10382 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HS-10382 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.